Trilaciclib
Trilaciclib is an orally bioavailable, short-acting CDK4/6 inhibitor (IC50 1-4 nM) that induces reversible G1 arrest. It is researched for mitigating chemotherapy-induced myelosuppression and enhancing antitumor immunity in various cancers, with applications in both in vitro cell cycle studies and in vivo preclinical models.
Product Specifications
CAS Number
1374743-00-6
Product Name Alternative
CDK6, CDK4, Trilaciclib
Field of Research
Cell Biology, Pharmacology & Drug Discovery
Purity
99.62% (May vary between batches)
Solubility
DMSO:4.5 mg/mL (10.08 mM)
Smiles
CN1CCN (CC1) c1ccc (Nc2ncc3cc4C (=O) NCC5 (CCCCC5) n4c3n2) nc1
Molecular Formula
C24H30N8O
Molecular Weight
446.55
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
20333111 3x 1.0 µg
FBXO4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
Sign In for Pricing
View Details K4867306 1.0 µg DNA
Mageb3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)
Sign In for Pricing
View Details 